Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC

NCT03445000 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT03445000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03445000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Terminated
Start date
November 6, 2018
Completion date
March 31, 2021
Enrollment
14 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, non-small cell lung cancer metastatic, non-small cell lung cancer recurrent